172 related articles for article (PubMed ID: 29076134)
21. PDL-1/PD1 inhibitors: antibody or antinobody?
Aoun F; Rassy EE; Assi T; Kattan J
Future Oncol; 2017 Aug; 13(19):1669-1671. PubMed ID: 28831825
[No Abstract] [Full Text] [Related]
22. Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma.
Saesoo S; Sathornsumetee S; Anekwiang P; Treetidnipa C; Thuwajit P; Bunthot S; Maneeprakorn W; Maurizi L; Hofmann H; Rungsardthong RU; Saengkrit N
Colloids Surf B Biointerfaces; 2018 Jan; 161():497-507. PubMed ID: 29128836
[TBL] [Abstract][Full Text] [Related]
23. [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].
Adam J; Tomasic G; Robert C
Ann Pathol; 2017 Feb; 37(1):55-60. PubMed ID: 28111041
[TBL] [Abstract][Full Text] [Related]
24. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.
Orecchioni S; Talarico G; Labanca V; Calleri A; Mancuso P; Bertolini F
Br J Cancer; 2018 May; 118(10):1329-1336. PubMed ID: 29695766
[TBL] [Abstract][Full Text] [Related]
25. Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study.
Hayano A; Komohara Y; Takashima Y; Takeya H; Homma J; Fukai J; Iwadate Y; Kajiwara K; Ishizawa S; Hondoh H; Yamanaka R
Anticancer Res; 2017 Oct; 37(10):5655-5666. PubMed ID: 28982883
[TBL] [Abstract][Full Text] [Related]
26. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
Siegel J; Totonchy M; Damsky W; Berk-Krauss J; Castiglione F; Sznol M; Petrylak DP; Fischbach N; Goldberg SB; Decker RH; Stamatouli AM; Hafez N; Glusac EJ; Tomayko MM; Leventhal JS
J Am Acad Dermatol; 2018 Dec; 79(6):1081-1088. PubMed ID: 30025829
[TBL] [Abstract][Full Text] [Related]
27. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
28. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
29. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.
Falchook GS; Leidner R; Stankevich E; Piening B; Bifulco C; Lowy I; Fury MG
J Immunother Cancer; 2016; 4():70. PubMed ID: 27879972
[TBL] [Abstract][Full Text] [Related]
30. Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis.
Ooi JD; Li M; Kourkoutzelos K; Yagita H; Azuma M; Holdsworth SR; Kitching AR
Nephrology (Carlton); 2015 Dec; 20(12):892-8. PubMed ID: 26043977
[TBL] [Abstract][Full Text] [Related]
31. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
[TBL] [Abstract][Full Text] [Related]
32. PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
Bagley SJ; Bauml JM; Langer CJ
Clin Adv Hematol Oncol; 2015 Oct; 13(10):676-83. PubMed ID: 27058572
[TBL] [Abstract][Full Text] [Related]
33. Vasculitis associated with immune checkpoint inhibitors-a systematic review.
Daxini A; Cronin K; Sreih AG
Clin Rheumatol; 2018 Sep; 37(9):2579-2584. PubMed ID: 29923081
[TBL] [Abstract][Full Text] [Related]
34. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
35. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
36. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
37. A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models.
Fan J; Zhuang X; Yang X; Xu Y; Zhou Z; Pan L; Chen S
Signal Transduct Target Ther; 2021 Sep; 6(1):320. PubMed ID: 34475375
[No Abstract] [Full Text] [Related]
38. An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.
Khedri M; Abnous K; Rafatpanah H; Ramezani M
J Recept Signal Transduct Res; 2018 Feb; 38(1):31-36. PubMed ID: 29252078
[TBL] [Abstract][Full Text] [Related]
39. The use of immunotherapy in the treatment of melanoma.
Achkar T; Tarhini AA
J Hematol Oncol; 2017 Apr; 10(1):88. PubMed ID: 28434398
[TBL] [Abstract][Full Text] [Related]
40. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]